Allarity Therapeutics, Inc. Impairment Charge on Reclassified Assets
Allarity Therapeutics, Inc. (ALLR) reported Impairment Charge on Reclassified Assets of $14.01 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentChargeOnReclassifiedAssets · last filed 2023-11-14
- Allarity Therapeutics, Inc. impairment charge on reclassified assets for the quarter ending 2022-06-30 was $0.00.
- Allarity Therapeutics, Inc. impairment charge on reclassified assets for the quarter ending 2022-03-31 was $14.01M.
| Period end | Impairment Charge on Reclassified Assets 3 month | Impairment Charge on Reclassified Assets 3 month as first filed | Impairment Charge on Reclassified Assets 6 month | Impairment Charge on Reclassified Assets 9 month |
|---|---|---|---|---|
| 2023-09-30 | $14.01M 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $14.01M 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $14.01M 10-Q · filed 2023-05-11 | $14.01K 10-Q · filed 2022-05-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |